Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Beauty Health ( (SKIN) ) has provided an announcement.
On May 21, 2025, The Beauty Health Company announced it had entered into exchange agreements to refinance its debt, exchanging $413.2 million of existing convertible notes for $250 million of new senior secured notes due 2028 and $143.4 million in cash. This move aims to strengthen the company’s financial position and extend debt maturity, allowing for greater investment in growth strategies, including product development and brand initiatives.
The most recent analyst rating on (SKIN) stock is a Hold with a $1.20 price target. To see the full list of analyst forecasts on Beauty Health stock, see the SKIN Stock Forecast page.
Spark’s Take on SKIN Stock
According to Spark, TipRanks’ AI Analyst, SKIN is a Neutral.
Beauty Health’s overall stock score reflects significant financial challenges, including high leverage and negative profit margins, which are partially offset by improved cash flow. The technical analysis shows moderate stock strength, and the earnings call provided a positive outlook despite some risks. Valuation remains a concern due to ongoing losses, while recent corporate events offer a potentially positive strategic direction.
To see Spark’s full report on SKIN stock, click here.
More about Beauty Health
The Beauty Health Company, listed on NASDAQ as SKIN, operates at the intersection of medtech and beauty, offering skin health experiences through brands like Hydrafacial™, SkinStylus™, and Keravive™. The company focuses on personalizing skin health for diverse demographics and is committed to sustainable business practices.
Average Trading Volume: 875,874
Technical Sentiment Signal: Sell
Current Market Cap: $206.6M
For a thorough assessment of SKIN stock, go to TipRanks’ Stock Analysis page.